At SCI, we are devoted to the international research, development, and implementation of stem cell therapy. We are also expanding our network with professionals, labs, clinics, hospitals, and nonprofit organizations. Our ultimate goal at SCI is to connect people who need treatment with the right dedicated solutions and professionals for their unique needs. At SCI, we believe such connections should be convenient and at your fingertips, just as so many other services are in modern society. We imagine a world where each and every person, no matter where they come from, will be able to connect with a Stem Cel Specialist instantly through our Stem Cell Innovations application (SCI Application), and in the same connection be able to decide when and how much confidential information to share with professionals.
Establishment of Camden RAD, LLC, a company devoted to stem cell research and development.
Q4 2017
Camden RAD, LLC is rebranded as Stem Cell Innovations, and a new company is established, based on blockchain technology.<br />
<br />
Advanced research begins to determine market and development opportunities.
Q1 2018
Attended Token 2049 conference in Hong Kong.<br />
<br />
Attended Stem Cell Summit at the University of California in Los Angeles (UCLA).<br />
<br />
Attended CBC conference in San Francisco, CA.<br />
Q2 2018
Attended ICO20 Summit in Santa Monica, CA.<br />
<br />
Integration of smart contract technology is established.<br />
<br />
Company headquarters incorporated in Gibraltar, GB.<br />
<br />
Strategic efforts toward development begins.<br />
<br />
Interviews with potential medical participants take place.
Q3 2018
Whitelist is scheduled to go live.<br />
<br />
Token Sale starts.
Q4 2018
Token Sale ends and min max caps are assessed.<br />
<br />
Distribution of Tokens to participants through ERC20 will commence.
Q1 2019
SCI will begin final testing and reporting based on blockchain technology being used.<br />
<br />
Creation of a non-identical patient identification factor on Passive Blockchain Node will be initialized.<br />
<br />
Demo testing for SCI Application v 1.0 will begin.
Q2 2019
Release of the SCI Application v1.1<br />
<br />
Enrollment begins for doctors, patients, and stem cell laboratories in the United States
Q3 2019
Release of Market Surveillance strategy for further growth<br />
<br />
Release SCI Application v2.0<br />
<br />
Enrollment begins for professionals, patients, and stem cell laboratories in Middle East and across North Africa.<br />
<br />
Announcement of first SCI Lab location and franchise expansion plan.
Q4 2019
Announcement of clinical development and research strategy in the stem cell field.<br />
<br />
Public announcement regarding SCI achievements to date.<br />
<br />
First ever online synthetic stem cell purchase through the SCI Application. Release SCI Application v3.0, fully functional platform for professionals and patients.
Q1 2020
Stem Cell Lab Evaluation report per first year of operation and development.<br />
<br />
Release SCI earnings and financials report.<br />
<br />
Release results of SCI's stem cell research and development to date.<br />
Q2 2020
Expansion of SCI stem cell labs and clinics in China, Japan, South Korea, and India.<br />
<br />
Begin charging membership fees (payable in Stem Cell Innovations tokens) for professional-facing portion of SCI application.
Q3 2020
Begin second phase of SCI stem cell research and development.<br />
<br />
Release SCI Application v3.5, including professional-facing component to help practitioners become more involved in the stem cell research space and contribute to the network.
Q4 2020
Expansion and acquisition of SCI stem cell labs and clinics in Europe.
Q1 2021
Release SCI earnings and financials report for second year operation and development.<br />
<br />
Release public update on SCI stem cell research and development.<br />
<br />
Stem Cell Lab Evaluation report for second year.
Q2 2021
Release SCI Application v4.0 including:<br />
<br />
A new platform for medical students, universities, and hospitals to engage with the SCI Application.<br />
<br />
Fully Functional EMR Worldwide Enforcing HIPPA and expanding of synthetic stem cell delivery to Latin America.
.png)
.png)
